Back to top

Analyst Blog

Drugstore chain retailer, Rite Aid Corporation’s (RAD - Analyst Report) same-store sales (comps) for the 5 weeks ended Jun 1, 2013 slipped 1.5%. The fall was due to a decline in pharmacy comps, partially offset by improved front-end comps.

Pharmacy comps for May fell 2.7% primarily due to a negative impact of approximately 373 basis points from generic drug introduction and a 0.3% drop in prescription counts. However, the company’s front-end comps rose 0.8%.

Rite Aid reported total drugstore sales of $2.423 billion for the month, with prescription sales constituting 67.0% of it. Third-party prescription sales accounted for 97.0% of pharmacy sales. The company’s drugstore sales for the month fell 1.5% from the year-ago figure of $2.459 billion.

For the 13-week period ended Jun 1, Rite Aid’s comps decreased 2.5% primarily due to a fall of 3.8% in Pharmacy comps, partially offset by an increase of 0.4% at front-end comps. In the said period, total drugstore sales decreased 2.8% to $6.264 billion from $6.441 billion in the comparable period of 2012.

Prescription sales comprised 67.5% of total drugstore sales, with prescription counts dropping 0.1%. Additionally, third-party prescription sales constituted 97.0% of the pharmacy sales.

Rite Aid, which trails Walgreen Co. (WAG - Analyst Report) and CVS Caremark Corp. (CVS - Analyst Report) in terms of store count, has persistently witnessed a decreasing sales trend over several quarters due to the introduction of lower cost generic (non-brand) drugs. Such non-branded drugs are less expensive in the market but generate higher gross margins for the company.

This is evident from Rite Aid’s performance in fourth-quarter fiscal 2013, when generic medication primarily drove its margin expansion. Going forward, this Zacks Rank #2 (Buy) stock is likely to focus on expanding its portfolio of generic medication, given the growing demand for such drugs.

However, Rite Aid’s generic drug sales could be adversely affected by Wal-Mart Stores Inc.’s (WMT - Analyst Report) foray into the retail generic drug market. Due to Wal-Mart’s wide array of manufacturers in India, Israel, and the U.S., the mass merchant can offer the particular drugs at a more discounted price compared with the average $10.00 generic drug co-pay.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%